Skip to main content
. Author manuscript; available in PMC: 2013 Feb 19.
Published in final edited form as: Clin Cancer Res. 2011 May 27;17(13):4331–4340. doi: 10.1158/1078-0432.CCR-11-0226

Figure 2.

Figure 2

Univariate overall survival (A and B) and disease-free survival (C and D) analysis for NGAL in patients with colorectal carcinoma. The patients with high NGAL expression had worse overall survival than those with low NGAL expression in the 227 CRC cases with the follow-up period longer than 5 years (A) and in the 145 patients with stage II CRC (B). For the 211 patients with stages I to III CRC, there was a trend that patients with high NGAL expression had worse disease-free survival time (C). For the stage II patients, the cases with high NGAL expression had worse disease-free survival than those with low NGAL expression (D).